May 20th, 12:30 PM

Therapeutic Monoclonal Antibodies to Prevent Tuberculosis Infection

Andrew Crowley  
*University of Massachusetts Medical School*

Chloe Emery  
*University of Massachusetts Medical School*

Gregory W. Martens  
*University of Massachusetts Medical School*, Gregory.Martens@umassmed.edu

*See next page for additional authors*

Follow this and additional works at: http://escholarship.umassmed.edu/cts_retreat

Part of the Immunoprophylaxis and Therapy Commons, Respiratory Tract Diseases Commons, Therapeutics Commons, Translational Medical Research Commons, and the Virology Commons

http://escholarship.umassmed.edu/cts_retreat/2014/posters/31

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Presenter Information
Andrew Crowley, Chloe Emery, Gregory W. Martens, Megan K. Proulx, Jon D. Goguen, Christopher M. Sassetti, and Colby A. Souders

Comments
Abstract of poster presented at the 2014 UMass Center for Clinical and Translational Science Research Retreat, held on May 20, 2014 at the University of Massachusetts Medical School, Worcester, Mass.

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

This is available at eScholarship@UMMS: http://escholarship.umassmed.edu/cts_retreat/2014/posters/31
Therapeutic Monoclonal Antibodies to Prevent Tuberculosis Infection

Andrew Crowley1*, Chloe Emery1*, Gregory Martens1, Megan Proulx2, Jon Goguen2, Christopher Sassetti2#, and Colby A Souders1#

1MassBiologics of the University of Massachusetts Medical School, Department of Product Discovery, 460 Walk Hill St, Boston, MA 02126.

2University of Massachusetts Medical School, Department of Microbiology and Physiological Systems, 5 Lake Ave North, Worcester, MA 01655

*These authors contributed equally to the work

#Co-PIs of work funded by a UMCCTS/MassBiologics NHMPP award

Corresponding Author: Colby.Souders@umassmed.edu, (617)-474-4050

Abstract:

*Mycobacteria tuberculosis* (Mtb) is a major cause of human morbidity and mortality. Transmission occurs through inhalation of aerosolized Mtb and the initial infection is believed to occur primarily in the alveolar macrophage, although Mtb can infect other cells residing in the lung including dendritic cells, pneumocytes and M cells. Several molecules derived from Mtb are involved in the attachment of the organism to host receptors (opsonic and non-opsonic), which have been reasonably well elucidated. However, a complete understanding of how Mtb attaches to the host and the relative importance of each mechanism on the outcome of infection remains elusive.

We hypothesize that protection from infection is possible by blocking the critical initial surface interactions of the organism with the host cell using specific monoclonal antibodies (mAbs). To develop effective mAbs, the outermost layers of Mtb, the capsule and outer membrane, were isolated and characterized by protein gel and LC/MS/MS. Approximately 1000 different proteins were identified in the isolations, of which ~25% were unique to one of the two fractions. The capsule or outer membrane preparations were used as antigens to immunize CD1 mice for up to 12 weeks to generate antibodies via traditional hybridoma generation. Antibodies were screened, selected and characterized by their ability to bind whole cell Mtb by ELISA, demonstration of unique heavy chain variable region sequence and binding specificity by Western Blot. Of approximately 1500 screened hybridomas, 30 lead mAbs have been isolated with specificity to various targets. Preliminary results suggest several of the lead mAb candidates are able to prevent Mtb-induced macrophage cell death *in vitro*. Future studies will attempt to confirm efficacy *in vivo* after aerosolized infection in mice with mAb-coated Mtb or parenteral administration of mAb(s). Targets of functional mAbs will be determined and these antigens could serve as viable candidates for vaccine development.